Adimarket , a division of Global Stem Cells Group, has signed an agreement to distribute Mystem stem cell technology in Latin America
MIAMI (PRWEB) December 06, 2015
Adimarket, Inc., a leading provider of in-office regenerative medicine solutions, has reached an agreement with MyStem to promote and distribute their stem cell technology products throughout Latin America.
MyStem develops and manufactures regenerative products for use in orthobiologics (ortho, trauma, spine), sports medicine, plastic surgery, aesthetics and dermatology treatments.
MyStem products include the innovative adipose-derived regenerative fraction device MyStem X2, a disposable collection and separation system for autologous adipose-derived mesenchymal stem cells (AdMSC). The MyStem device collects regenerative fraction without any extensive tissue manipulation, according to requirements established under international laws, in a completely safe closed sterile system. The regenerative fraction separation process is based on cells intrinsic parameters in a liquid fraction according to fluidic laws.
After the separation process, a concentrated regenerative cells fraction suspension is ready for use in a one-step procedure. MyStem offers an enhanced method for isolating and quickly expanding a robust population of mesenchymal stem cells (MSCs) derived from lipoaspirate in less than 30 minutes. This isolation process yields a generous population of ASCs (~100,000 cells per 100 ml of blood/saline collected from sonicated lipoaspirate) with differentiation potential, characteristic cell surface markers, and proliferative lifespan indistinguishable from MSCs extracted from bone marrow (BMSCs) or conventionally processed ASCs.(1,2 ).
The MyStem process is simple, with no centrifuge needed. Quality sampling is not operator dependent, and collects up to 1,000 times more than the bone marrow MSC + growth factors.
MyStem Managing Director Pier Ivona calls the new alliance with Adimarket a natural fit, since both companies share a deep commitment to getting critical regenerative medicine tools to the clinicians in Latin America who need them.
“Global Stem Cells Group and MyStem are both pioneers in stem cell research and innovation, and we share the same goal of making stem cell therapies available globally,” Ivona says. “We believe that this is the perfect time to team with Global Stem Cells Group and its Adimarket division to distribute MyStem technology throughout Latin America’s fast-growing medical community.”
The collaboration between Global Stem Cells Group and MyStem reflects one more step toward GSCG’s commitment to expanding its presence in communities that need and deserve access to cutting-edge regenerative medicine, not only in Latin America but also worldwide.
For more information, visit the Adimarket website, email info(at)adimarket(dot)net, or call +1 305 560 5337.
Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor's office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.
Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Wilmington, Delaware-based MyStem is dedicated to contributing to human welfare through the design, manufacture, and sale of regenerative medicine instruments or appliances designed to alleviate pain and restore health. MyStem specializes in regenerative medicine treatments for: spine, ortho, sports medicine, burn and wound healing, CMF (cranio maxillo facial), chronic wounds and diabetic foot wounds.